Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.38 |
| ▸ | F2R | P25116 | 10/20 | 0.45 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5490249 | 1.00 | F2R (0.45) | F2RMAOBBCHEMAOAACHE | |
| SCHEMBL4337619 | 0.99 | F2R (0.46) | F2RMAOBBCHEMAOAACHE | |
| SCHEMBL13750962 | 0.99 | F2R (0.46) | F2RMAOBBCHEMAOAACHE | |
| Bromide SCHEMBL4330579 | 0.91 | F2R (0.43) | F2RMAOBBCHEMAOAACHE | |
| SCHEMBL13750959 | 0.90 | F2R (0.44) | F2RMAOBBCHEMAOAACHE | |
| SCHEMBL4335548 | 0.90 | F2R (0.44) | F2RMAOBBCHEMAOAACHE | |
| Bromide SCHEMBL4333217 | 0.89 | F2R (0.47) | F2RMAOBBCHEMAOAACHE | |
| Bromide SCHEMBL4326320 | 0.89 | F2R (0.47) | F2RMAOBBCHEMAOAACHE | |
| Bromide SCHEMBL4329592 | 0.89 | F2R (0.42) | F2RMAOBBCHEMAOAACHE | |
| Bromide SCHEMBL4336799 | 0.89 | F2R (0.46) | F2RMAOBBCHEMAOAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1386912-B1 | CYCLIC AMIDINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2009-03-18 | — | — | EP | claimed |
| US-20090215795-A1 | CYCLIC AMIDINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-1386912-B1 | CYCLIC AMIDINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-7476688-B2 | Cyclic amidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-13 | — | — | US | disclosed |
| US-20040254376-A1 | Cyclic amidine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1386912-A1 | CYCLIC AMIDINE DERIVATIVE | Eisai Co., Ltd. (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254376-A1 | Cyclic amidine derivative | ARGLU1, ARG1, PRMT1 | ACHE 3494/4885F2R 2745/4885MAOB 3293/4885 |
| US-20090215795-A1 | CYCLIC AMIDINE DERIVATIVES | H1-10, H1-3, H1-4 | ACHE 2173/4885F2R 1447/4885MAOB 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.